{"id":129,"date":"2010-03-30T08:43:37","date_gmt":"2010-03-30T08:43:37","guid":{"rendered":"http:\/\/people.unica.it\/mvgebming\/?page_id=129"},"modified":"2010-03-30T08:43:37","modified_gmt":"2010-03-30T08:43:37","slug":"vizier","status":"publish","type":"page","link":"https:\/\/people.unica.it\/mvgebming\/vizier\/","title":{"rendered":"VIZIER"},"content":{"rendered":"<p><a href=\"http:\/\/people.unica.it\/mvgebming\">Home <\/a>\u2013 <a href=\"http:\/\/people.unica.it\/mvgebming\/funding\/\">Funding <\/a>\u2013 <strong><strong><a href=\"http:\/\/people.unica.it\/mvgebming\/european-projects\/\">European Projects <\/a><\/strong><\/strong>&#8211; <a href=\"http:\/\/people.unica.it\/mvgebming\/completed-projects\/\">Completed projects\u00a0\u00a0<\/a>&#8211;<span style=\"color: #ffffff\"> \u00a0<strong>VIZIER <\/strong><\/span><\/p>\n<p><span style=\"color: #ffffff\"><strong>VIZIER &#8220;Comparative Structural Genomics of Viral Enzymes Involved in Replication&#8221; (October 2004 &#8211; October 2008)<br \/>\n<\/strong><br \/>\nType of project: Integrated projectTotal EU grant: \u20ac 1.964.897<\/span><\/p>\n<p><span style=\"color: #ffffff\">Section grant: \u20ac 373.934,00<\/span><\/p>\n<p><span style=\"color: #ffffff\">Role: Partner<\/span><\/p>\n<p><span style=\"color: #ffffff\">This project aimed to perform a ground-breaking impact on the identification of potential new drug targets against RNA viruses through comprehensive structural characterization of the replicative machinery of ~300 RNA viruses. RNA viruses are major human pathogens (&gt;350 identified) causing millions of deaths annually.<br \/>\nThe VIZIER team brought together the leading authorities on RNA viruses available in EU &amp; more, with P4 facilities, as well as leaders in the field of structural genomics, with an adapted Management &amp; Training structure.<br \/>\nVIZIER aimed to characterise RNA viruses (no DNA stage in their repl. cycle) of 3 genetically different classes: double-stranded and single stranded RNA viruses with positive &amp; negative polarity. Their replicative machineries are the most conserved and essential viral components, thus are attractive targets for antivirus therapy. The core enzymes\/proteins of the replication machinery (polymerases, helicases, capping enzymes, NTPases, proteases, ancillary replicative proteins) were characterized and compared.<br \/>\nOne unique feature of VIZIER was the integration of major structural effort within a broad multidisciplinary study, having virology upstream and target validation (lead design) downstream. As a result, the implementation plan of the VIZIER project was structured into 5 interacting scientific sections: (i) bioinformatics, for genome annotation, target selection and data integration; (ii) virus production and genome sequencing; (iii) HTP protein production (2000-3000 targets); (iv) HTP crystallization and structural determination and (v) target validation, to assess the function of enzymes and design strategies for virus inhibition. New tools for protein production and distributed X-ray crystallography were developed and validated. This latter aspect provided a new mechanism for the fast dissemination of the gained knowledge and expertise within the European Union, inside and outside the project.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Home \u2013 Funding \u2013 European Projects &#8211; Completed projects\u00a0\u00a0&#8211; \u00a0VIZIER VIZIER &#8220;Comparative Structural Genomics of Viral Enzymes Involved in Replication&#8221; (October 2004 &#8211; October 2008) Type of project: Integrated projectTotal EU grant: \u20ac 1.964.897 Section grant: \u20ac 373.934,00 Role: Partner This project aimed to perform a ground-breaking impact on the identification of potential new drug targets against RNA viruses through comprehensive structural characterization of the replicative machinery of ~300 RNA viruses. RNA viruses are major human pathogens (&gt;350 identified) causing millions of deaths annually. The VIZIER team brought together the leading authorities on RNA viruses available in EU &amp; more, <a href='https:\/\/people.unica.it\/mvgebming\/vizier\/' class='excerpt-more'>[&#8230;]<\/a><\/p>\n","protected":false},"author":49,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-129","page","type-page","status-publish","hentry","category-1-id","post-seq-1","post-parity-odd","meta-position-corners","fix"],"_links":{"self":[{"href":"https:\/\/people.unica.it\/mvgebming\/wp-json\/wp\/v2\/pages\/129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/people.unica.it\/mvgebming\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/people.unica.it\/mvgebming\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/people.unica.it\/mvgebming\/wp-json\/wp\/v2\/users\/49"}],"replies":[{"embeddable":true,"href":"https:\/\/people.unica.it\/mvgebming\/wp-json\/wp\/v2\/comments?post=129"}],"version-history":[{"count":1,"href":"https:\/\/people.unica.it\/mvgebming\/wp-json\/wp\/v2\/pages\/129\/revisions"}],"predecessor-version":[{"id":130,"href":"https:\/\/people.unica.it\/mvgebming\/wp-json\/wp\/v2\/pages\/129\/revisions\/130"}],"wp:attachment":[{"href":"https:\/\/people.unica.it\/mvgebming\/wp-json\/wp\/v2\/media?parent=129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}